Traws Pharma, Inc. (TRAW)
TRAW moved a median of -0.33% 30 minutes after news, and -2.88% by the close. How TRAW actually reacts to news — the realized, point-in-time move the market made, measured across 235 labeled events over the last three years with zero look-ahead.
TRAW’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 223 |
| 30-min | -0.33% | 41% | 228 |
| 60-min | -0.60% | 45% | 230 |
| to close | -2.88% | 36% | 231 |
| Middle 50% of TRAW reactions | -4.50% to +1.85% |
|---|---|
| Median reaction (30-min) | -0.33% |
| Measured reactions | 235 |
Half of all Traws Pharma, Inc. news events land between -4.50% and +1.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TRAW moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TRAW's baseline. Nothing else.
Recent TRAW events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form PRE 14A Traws Pharma, Inc. For: Oct 08 | SEC filing · Form PRE | SEC EDGAR | -5.52% | -4.69% | |
| Form 10-Q Traws Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.57% | -3.57% | |
| Form 8-K Traws Pharma, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.57% | -3.57% | |
| Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | -3.57% | -3.57% | |
| Form 8-K Traws Pharma, Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -0.49% | +0.34% | |
| Form 8-K Traws Pharma, Inc. For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -2.12% | -11.36% | |
| Form EFFECT Traws Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.29% | +8.57% | |
| Form 8-K Traws Pharma, Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | +8.57% | |
| Form S-3 Traws Pharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.95% | -6.38% | |
| Form 8-K Traws Pharma, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -2.77% | +6.39% | |
| Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | Press release | GlobeNewswire | -2.77% | +6.39% | |
| Form 8-K Traws Pharma, Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -30.66% | |
| Traws Pharma Provides Regulatory Update on Influenza Program | Press release | GlobeNewswire | -0.46% | -30.66% | |
| Form ARS Traws Pharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.67% | -2.67% | |
| Form DEF 14A Traws Pharma, Inc. For: Jul 08 | SEC filing · Form DEF | SEC EDGAR | +1.67% | -2.67% | |
| Form DEFA14A Traws Pharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.67% | -2.67% | |
| Form 8-K Traws Pharma, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | -6.13% | |
| Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Press release | GlobeNewswire | -1.25% | -6.13% | |
| Form 8-K Traws Pharma, Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | -6.13% | |
| Form PRE 14A Traws Pharma, Inc. For: May 19 | SEC filing · Form PRE | SEC EDGAR | -1.25% | +1.25% | |
| Form EFFECT Traws Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.19% | -6.38% | |
| Form 10-Q Traws Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.52% | +21.29% | |
| Form 8-K Traws Pharma, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +4.52% | +21.29% | |
| Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results | Press release | GlobeNewswire | +4.52% | +21.29% | |
| Form S-3 Traws Pharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +9.91% | -9.01% | |
| Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections | Press release | GlobeNewswire | +1.70% | +5.83% | |
| Form 10-K/A Traws Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +4.93% | |
| Form 10-K Traws Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.60% | -3.20% | |
| Form 8-K Traws Pharma, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | -14.58% | |
| Traws Pharma Announces Up to $60 Million Private Placement Financing | Press release | GlobeNewswire | -2.08% | -14.58% | |
| Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights | Press release | GlobeNewswire | -5.60% | -3.20% | |
| Form NT 10-K Traws Pharma, Inc. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -3.89% | -7.78% | |
| Form 8-K Traws Pharma, Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.97% | |
| Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza | Press release | GlobeNewswire | +0.00% | +3.97% | |
| Form 8-K Traws Pharma, Inc. For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | +14.34% | |
| Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza | Press release | GlobeNewswire | +0.82% | +14.34% | |
| Form 8-K Traws Pharma, Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | +1.54% | +23.85% | |
| Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients | Press release | GlobeNewswire | +1.54% | +23.85% | |
| Form 8-K Traws Pharma, Inc. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -11.91% | -36.07% | |
| Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients | Press release | GlobeNewswire | -11.91% | -36.07% | |
| Form 8-K Traws Pharma, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -11.91% | -36.07% | |
| Form 8-K Traws Pharma, Inc. For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -8.82% | |
| Form 10-Q Traws Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.22% | — | |
| Form 8-K Traws Pharma, Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -1.22% | — | |
| Traws Pharma Reports Third Quarter 2025 Results and Business Highlights | Press release | GlobeNewswire | -1.22% | — | |
| ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials | Press release | PR Newswire | -0.98% | -4.59% | |
| Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. | Press release | PR Newswire | +0.00% | -0.76% | |
| Form 8-K Traws Pharma, Inc. For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +7.72% | |
| Form 8-K Traws Pharma, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | +2.08% | |
| Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 | Press release | GlobeNewswire | -1.90% | +2.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TRAW section they belong to.
Where else TRAW is measured.
TRAW earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Traws Pharma, Inc.'s median reaction calculated?
Every labeled TRAW news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 235 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of TRAW's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TRAW's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.